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Introduction
Newborn screening is now integrated into routine neonatal practice in many parts of 
the world, and the overall ethical acceptability of newborn screening programmes is 
well recognised.1 Although the procedure corresponds in essence to genetic screening, 
it is seldom referred to as such and is often categorised as a public health disease 
prevention programme aimed at early detection and treatment of asymptomatic 
newborns affected by specific treatable disorders. Accordingly, the overall ethical 
issues that have been dealt with extensively in the context of medical genetics, such 
as the principle of autonomy and the requirement for informed decision-making, have 
been considered less significant with regard to publicly mandated newborn screening, 
because these newborn public health programmes are believed to be implemented in 
the paediatric interests of children and therefore override the need for an explicit or 
written informed consent. The WHO considers that newborn screening should be 
mandatory if early diagnosis and treatment will benefit the newborn.3
As scientific and genetic technologies advance, classical newborn screening 
programmes aimed at detecting only preventable diseases are now being revisited 
and expanded. In some countries, they are being redesigned to include new disorders 
which are not in total compliance with the long-established WHO criteria of 
conditions suitable for screening. Using the same blood sample collected to screen 
1 Kerruish, N.J. and, Robertson, S.P., ‘Newborn Screening: New Developments, New 
Dilemmas’, (005) 31 J. Med. ������, 393-8. 
 Laberge, C., Kharaboyan, L. and Avard, D., ‘Newborn Screening, Banking, and 
Consent’, 
(00) (3) Gen�d��, available at: http://www.humgen.umontreal.ca/int/GE/en/00-
3.pdf.   
3 World Health Organization (WHO), Propo�ed In�erna��onal Gu�del�ne� on �����al 
I��ue� �n Med��al Gene���� and Gene��� Serv��e�, Geneva, December 15 and 16, 1997, 
available at: http://whqlibdoc.who.int/hq/1998/WHO_HGN_GL_ETH_98.1.pdf (accessed 
11/08/0).
 Wilson, J. and Jungner, G., Pr�n��ple� and Pra����e of S�reen�ng for D��ea�e, Geneva, 
World Health Organization (Public Health Paper), 1968.
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for classical disorders like phenylketonuria (PKU) and congenital hypothyroidism, 
laboratories are now able to examine DNA and test newborn bloodspots for conditions 
which are still not treatable, to identify a genetic predisposition not manifested until 
adulthood, to indicate genetic susceptibility to common multifactorial diseases and, 
finally, to reveal incidental results such as carrier status for both treatable diseases 
and untreatable conditions. 
There are many disorders currently being considered for inclusion in newborn 
screening programmes, such as inborn errors of metabolism,5 cystic fibrosis,6 
muscular dystrophy,7 and Type I diabetes.8 Here we will focus on one illustrative 
example: newborn screening for sickle cell diseases (SCD). Sickle cell disease 
is an example of a genetic condition that is considered a global health problem. 
Increasingly, industrialised countries are integrating sickle cell disease into their 
newborn screening programmes.9 Screening for SCD can occur during the prenatal 
or neonatal period. In this chapter we will focus on neonatal screening.
Although sickle cell disease can be treated through early detection and supportive 
therapies, neonatal screening for sickle cell disease is controversial and raises new 
challenges. Screening programmes provide clinical advantages, but there is also 
the risk of harm. In particular, there are three socio-ethical issues we would like to 
explore. First, as a result of neonatal screening and without having requested the 
information, we can identify carriers of the sickle cell trait at a time when concern 
about carrier status may not be a priority. Second, there are a number of approaches 
to neonatal screening for SCD. For example, infants can be screened on a selective 
basis (only high-risk infants) or by using a universal approach (all newborns). The 
issue of whether a programme screening for SCD should be universal or selective 
raises concerns about equity, the risk of discrimination and cost. Third, given the 
trend to promote community engagement, and the mounting pressure from advocacy 
groups to expand newborn screening programs, a decision to introduce newborn 
screening for SCD must proceed with careful consideration of the relevant ethical 
and social issues. This chapter does not discuss SCD newborn screening as part of 
the overall newborn screening programme or whether it should be integrated with 
the current neonatal screening programmes.
In the first part of this chapter, we will examine the rationale for sickle cell 
screening, including background, prevalence, and program description. This will be 
5 Seymour, C.A., Thomason, M.J., Chalmers, R.A.,  e� al., ‘Newborn Screening for Inborn 
Errors of Metabolism: A Systematic Review’, (1997) I Heal�� Te��nology A��e��men�.
6 Wald, N.J.  and Morris, J.K., ‘Neonatal Screening for Cystic Fibrosis’, (1998) 316 
B.M.J., 0-05.
7 Parsons, E.P., Bradley, D.M. and Clarke, A.J., ‘Newborn Screening for Duchenne           
Muscular Dystrophy’, (003) 88 Ar��. D��. C��ld, 91-9.
8 Bennett, J.S., Baughcum, A.E., Carmichael, S.K., She, J.X. and Schatz, D.A., 
‘Maternal Anxiety Associated with Newborn Genetic Screening for Type 1 Diabetes’, (00) 
7 D�abe�e� Care, 39-7.
9 Weatherall, D.J.  and Clegg, J.B., ‘Inherited Haemoglobin Disorders: An Increasing 
Global Health Problem’, (001) 79 Bulle��n of ��e World Heal�� Organ�za��on, 70-1.
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followed by a discussion of ethical and social issues, such as the identification of 
carriers, the constraints of using selective or universal approach for such programmes, 
and the pressures exerted on decision-makers by advocacy groups.
The Rationale for Neonatal Screening of Sickle Cell Disease
Ba�kground
Sickle cell disease (SCD) consists of a group of life-threatening, genetically inherited 
disorders, characterised by large amounts of abnormal haemoglobin in the red blood 
cells. Most infants with SCD are healthy at birth and become symptomatic later, in 
infancy or childhood. Affected infants generally present clinically during infancy or 
early childhood with painful swelling of the hands and feet (dactylitis), pneumococcal 
sepsis or meningitis, severe anaemia and acute spleen enlargement, acute chest 
syndrome, pallor, jaundice, or splenomegaly.10 The long-term consequences of SCD 
include chronic organ damage, such as degeneration of the kidneys, bones and joints, 
and chronic pain and disability, which compromise quality of life. These persons live 
under the possibility of early sudden death related to the disease11 and the lifespan 
varies between  years for males and 6 years for females.1 
With the exception of bone marrow or stem cell transplantation, only available for 
a limited number of patients with compatible donors, there is currently no definitive 
cure for SCD.13 Nevertheless, improvements in the medical care of children with 
SCD have increased their life expectancy and studies have shown that prognosis 
for patients has improved considerably through early diagnosis and treatment such 
as the early use of prophylactic penicillin and ongoing effective management of 
infections in children with the condition.1 
Prevalen�e
The disease mostly affects people whose ancestors are from Africa but is also 
prevalent in people of Mediterranean, Caribbean, South and Central American, 
10 American Academy of Pediatrics (AAP), ‘Health Supervision for Children with Sickle 
Cell Disease – Policy Statement’, (00) 109(3) Ped�a�r���, 56-35.
11 Thomas, V.J.  and Taylor, L.M., ‘The psychosocial experience of people with sickle 
cell disease and its impact on quality of life: Qualitative findings from focus groups’, (2002) 
7 Br����� Journal of Heal�� P�y��ology, 35-63.
1 Quinn, C.T., Rogers, Z.R., Buchanan, G.R., ‘Survival of children with sickle cell 
disease’, (00) 103(11) Blood, 03-7; Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., 
Castro, O., Steinberg, M.H., e� al., ‘Mortality in sickle cell disease: Life expectancy and risk 
factors for early death’, (199) 330 New �ngland Journal of Med���ne, 1639-3.
13 Weatherall, Clegg, lo� ���. 
1 Ballas, S.K., ‘Sickle Cell Disease: Clinical Management’, (1998) 11 Cl�n��al 
Haema�ology, 185-1. 
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Middle Eastern and Indian ancestry.15 The population at risk of SCD in Canada is 
unknown, and there are no available statistics to show whether there has been an 
increase in sickle cell disease in Canada over recent years as a result of increased 
migration.16 Estimates indicate that, in the United Kingdom, the prevalence of 
sickle cell disease and other haemoglobinopathies (genetically inherited disorders 
of haemoglobin) amongst newborns is now higher (1:2380) than cystic fibrosis 
(1:500),17 a disease that is predominantly prevalent in Caucasian populations18 and 
that has received much more attention than SCD.19 
Type� of S�reen�ng Programme�
Newborn screening aims to identify affected infants and begin preventive treatment 
before disease manifestation. Outside of Canada (e.g. in the US, the UK and 
France), newborn screening for sickle cell disease has generally been accepted as 
an effective intervention. However, an important drawback is the lack of consistent 
policies for SCD screening.0 For example, Wertz reported that in the United States, 
where programmes for sickle cell anaemia screening exist, differences exist among 
primary care physicians in the commitment to, and acceptability of, screening of 
all newborns, with 71 percent of paediatricians, 6 percent of obstetricians, and 0 
percent of family practitioners agreeing that at risk groups should be screened.1
Neonatal screening programmes can be offered universally or selectively. 
Universal screening is generally considered a routine public health intervention 
offered to the entire newborn population or to all pregnant women. In fact, universal 
neonatal screening for SCD has been implemented in most of the United States 
and in all of England as of April 005.3 In contrast to universal screening, selective 
or targeted screening concentrates on subpopulations with the aim of identifying 
high-risk infants and, indirectly, of identifying high-risk parents to offer them the 
opportunity of screening in future pregnancies. 
15 American Academy of Pediatrics, �upra note 10.
16 D. Souli�res, hematologist, personal communication.    
17 Streetly, A., Pol��y De����on for Implemen��ng Neona�al S�reen�ng for S��kle Cell 
D��ea�e, NHS Sickle & Thalassaemia Screening Programme, 00.
18 Parsons, Bradley, �upra ���., note 7.
19 Kmietowicz, Z., ‘Screening for Sickle Cell Disease and Thalassaemia Saving Lives’, 
(00) 39 B.M.J., 69. 
0 Streetly, A., ‘A National Screening Policy for Sickle Cell Disease and Thalassaemia 
Major for the United Kingdom’, (000) 30 B.M.J., 1353-.  
1 Wertz, D., ‘Ethical Issues in Pediatric Genetics’, (1998) 6 Heal�� Law Journal, 3-.
 National Newborn Screening and Genetics Resource Center (NNSGRC), U.S. Na��onal 
S�reen�ng S�a�u� Repor�, Austin, July 5, 00, http://genes-r-us.uthscsa.edu/nbsdisorders.pdf 
(accessed on 03/08/0).
3 NHS Sickle Cell and Thalassaemia Screening Programme, Pol��y for Newborn 
S�reen�ng, London, July 00, http://www-phm.umds.ac.uk/haemscreening/Documents/
NewbornScreeningPolicy.pdf (accessed on 0/08/0).
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The decision whether to adopt a universal or selective strategy rests with public 
health authorities and involves complex arguments about the risk of discrimination, 
equity, and cost-effectiveness. Although deciding on a screening approach is not an 
easy task, long-standing principles have been established to guide policy-makers in 
their decision-making. 
Perhaps the most cited source of screening criteria are the 1968 Wilson and 
Jungner principles of early disease detection.5 Essentially, they prescribe that 
conditions that are screened for should present an important health problem (i.e. be 
relatively prevalent); that an acceptable treatment be available to treat the screened 
condition; that facilities for diagnosis and treatment be widely available; that the cost 
(including diagnosing and treating patients) be economically balanced in relation to 
possible expenditure on medical care as a whole; and that diagnosed patients benefit 
from timely follow-up services.
A condition that complies with the above criteria is suitable for universal newborn 
screening. Although there is no definitive cure for SCD, it does fit the 1968 criteria: 
increased survival and health development of children with the condition is largely 
attributed to neonatal screening with prompt prophylactic penicillin treatment and to 
the effective management of infections.6,7,8 Because of this, the establishment of a 
newborn screening programme for sickle cell disease has been described as justifiable 
and unquestionable.9 Accordingly, since the publication of the NIH consensus 
statement on mandatory newborn screening for haemoglobinopathies in 1987,30 8 
American states as well as the District of Columbia have implemented universal 
newborn screening programmes for SCD.31 Moreover, as of April 005, all babies in 
England are being screened for SCD as part of the centralized newborn programme, 
which screens for phenylketonuria (PKU) and congenital hypothyroidism.
 Aspinall, P.J., Dyson, S.M.  and Anionwu, E., ‘The Feasibility of Using Ethnicity as 
a Primary Tool for Antenatal Selective Screening for Sickle Cell Disorders: Pointers from 
Research Evidence’, (003) 56 So��al S��en�e & Med���ne, 85-97.
5 Wilson, Jungner, �upra ���., note .
6 Zeuner, D., Ades, A.E., Karnon, J., Brown, J., Dezateux, C. and Aninowu, E.N., 
‘Antenatal and Neonatal Haemoglobinopathy Screening in the UK: Review and Economic 
Analysis’, (1999) 3(11) Heal�� Te��nology A�e��men�.
7 Davis, S.C., Cronin, E., Gill, M., Greengross, P., Hickman, M. and Normand, C. 
‘Screening for Sickle Cell and Thalassaemia: A Systematic Review with Supplementary 
Research’, (000) (3) Heal�� Te��nology A��e��men�.
8 NIH Consensus Development Program, Newborn S�reen�ng for S��kle Cell D��ea�e 
and O��er Hemoglob�nopa���e�: Na��onal In����u�e� of Heal�� Con�en�u� Developmen� 
Conferen�e S�a�emen�, April 6-8, 1987, http://consensus.nih.gov/cons/061/061_statement.
htm (accessed on 1/09/0).
9  Streetly, �upra ���., note 0.
30 Consensus Conference, ‘Newborn Screening for Sickle Cell Disease and Other 
Hemoglobinopathies’, (1987) 58 J.A.M.A., 105-9. 
31 National Newborn Screening and Genetics Resource Center, �upra ���., note .
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In instances where the disease is not prevalent in all regions or in all spheres of 
the population, authorities might opt for a targeted approach instead of a universal 
screening programme. For example, France has chosen to offer SCD screening to 
all high-risk infants3 by adopting a targeted screening approach in metropolitan 
areas, where infants are offered sickle cell screening if they fall under one of the 5 
criteria defined by the Association Française pour le Dépistage et la Prévention des 
Handicaps de l’Enfant.33 The 5 criteria are as follows: 1) if one of the two parents is 
originally from a country where the incidence of SCD is significant; 2) if one of the 
parents is from one of the above countries and the other is from Asia; 3) if the mother 
is at risk and the father is not known; ) if a parent suffers from a haemoglobin 
disorder or is aware of any family history in this regard; and 5) if there is any doubt 
with regard to the  previous points. A concern with this approach is that some 
infants belonging to high-risk groups may be difficult to identify.3 Following the 
introduction of the SCD screening programme there is evidence that early sudden 
death for children born with SCD is rare. However, follow-up studies of the long-
term impact on reducing morbidity and mortality are lacking.35
Due to global migration, it is estimated that immigrants from visible minorities 
account for 11. percent of the Canadian population.36 The greatest concentration of 
visible minorities is in large urban areas, with nearly  percent living in Toronto, 
18 percent in Vancouver and 13 percent in Montreal.37 Within the province of 
Quebec, Montreal is home to 9 percent of the black population (from areas like the 
Caribbean, French Antilles and northern Africa) as well as immigrants from Arab/
West Asian countries.38 Therefore, a high concentration of SCD carriers or patients is 
likely in major Canadian cities. However, in the absence of a screening programme 
of neonates for SCD, in Montreal and elsewhere, small selective programmes, 
initiated only by individual clinicians, currently operate in Montreal.39 In Toronto, 
a presentation to ‘The Commission on the Future of Health Care in Canada’ draws 
3 �riard, �.�., ��e dépistage néonatal de la drépanocytose en métropole’, (2000) 39            La 
Dépê��e.
33 Association française pour le Dépistage et la Prévention des �andicaps de l’�nfant,            
Gu�de pra��que� pour le� profe���onnel� de �an�é – Le dép���age néona�al, March 001.
3 Cronin, E.K., Normand, C., Henthorn, J.S., Hickman, M.  and Davies, S.C., ‘Costing 
model for neonatal screening and diagnosis of haemoglobinopathies’, (1998) 79 Ar��. D��. 
C��ld. Fe�al Neona�al �d., F161-7.
35 Farriaux, �.-P., ��e dépistage néonatal de la drépanocytose’ (2003)         Ann B�ol Cl�n, 61: 
376-8.
36 Compiled from the 001 Statistics Canada Census website.
37 Statistics Canada, ‘1996 Census: Ethnic Origin, Visible Minorities’, T�e Da�ly 
Tue�day, February 17, 1998: http://www.statcan.ca/Daily/English/98017/d98017.htm 
(accessed 01/08/05).
38 Id.
39 Edgar Delvin, personal communication.
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attention to the need for guidelines, education, and training regarding sickle cell 
disease.0
Socio-ethical Concerns Related to Screening for SCD in Newborn Screening 
Programmes
Classical newborn screening usually occurs in the absence of explicit written parental 
consent.1 However, for every one affected child, haemoglobin electrophoresis also 
identifies around 50 carriers who require follow-up because their parents may 
be at risk and therefore in need of genetic counselling. While withholding carrier 
information from parents is unacceptable, no consent to knowledge of carrier status 
is obtained prior to screening. If consent was required, some believe that parental 
refusal could jeopardise the overall preventive goals of newborn screening.3 
Policymakers must face the difficult issue of carrier information when deciding 
whether or not to include the disease in universal newborn screening panels. A second 
dilemma decision-makers face is determining the type of screening programme most 
appropriate for a certain population given the constraints of costs and the selective 
profiling on the basis of ethnicity. A final issue that will be discussed pertains to 
the pressures exerted by patient advocacy groups to include new diseases in the 
universal newborn screening programme.
The Identification of Carriers and Incidental Results
Perhaps the most critical issue related to the implementation of a universal SCD 
screening program is that, in addition to finding affected newborns, disease 
screening also identifies carriers. Detection of the sickle cell trait in newborns can 
0 Sickle Cell Parents’ Support Group (prepared by Anne C.D. Clarke), ‘Presentation to 
the Commission on the Future of Health Care in Canada: The Care and Treatment of Canada’s 
Multi-Racial Population’, 8 May 00.
1 Avard, D. and Knoppers, B.M., ‘Screening and Children Policy Issues for the New 
Millenium’, (001) (3) ISUMA, 6-57.
 Council of Regional Networks for Genetics Services (CORN), ‘US Newborn Screening 
System Guidelines II: Follow-up of Children, Diagnosis, Management, and Evaluation’, 
(000) 137() J. Ped�a�r���, S1.
3 Stewart, R., Oliver, S., ‘What is known about communication with parents about 
newborn bloodspot screening?’, UK Newborn Screening Programme Centre, London: http://
www.newbornscreening-bloodspot.org.uk 
 Screening for sickle cell syndromes is unique because both homozygotes and 
heterozygotes may be detected during screening. Indeed approximately 50 infants who are 
carriers of haemoglobin variants are identified for every one individual who is detected with 
sickle cell disease. See Council of Regional Networks for Genetic Services, Gu�del�ne� for 
Follow-up of Carr�er� of Hemoglob�n Var�an�� De�e��ed by Newborn S�reen�ng, Texas, 
September 10, 1995: http://www.gemdatabase.org/gemdatabase/docs/HemGuide.pdf (date 
accessed: August 6, 00).
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offer opportunities for extended family testing and genetic counselling to parents for 
future reproductive choices: if an infant is a carrier, one or both parents are carriers. 
This information is useful to parents if they do not know their carrier status. 
However, identifying carriers raises a number of ethical dilemmas for the family. 
First, while identification of carriers may be beneficial for the parents, birth is 
generally considered a poor time for communicating carrier screening information. 
�oreover, this information is of minimal benefit to the child; indeed, it may not be 
useful until the child reaches adolescence or reproductive age. There is no certainty 
that the genetic information will reach the child in an understandable form and at the 
appropriate time for the benefits to accrue: i.e. during adolescence or adulthood.5 
Additional disadvantages of knowing carrier status include alteration of self-esteem,6 
impact on a family’s perception of the child,7 lack of choice to be tested,8 increased 
anxiety,9 blaming oneself for the condition and possible discrimination against the 
child in education, insurance and employment.50
Past experiences have demonstrated that, in the absence of proper public education 
and parental counselling, confusion about the significance of carrying the common 
sickle cell trait (about 1 in 1 African Americans are carriers51) and the rare sickle cell 
anaemia (with a frequency of 1 in 600) has led to discrimination and stigmatisation.5 
Consequently, with the establishment of a newborn SCD program, the detection of 
carriers (both parents and children) should be accompanied by adequate counselling. 
Furthermore, the information provided during the screening programme and follow-
up should specifically describe the characteristics of carrier screening. 
While identification of carrier status has no implication whatsoever for the health 
or the medical care of the newborn, it increases parents’ knowledge of haemoglobin 
variants so that they will not confuse benign states with the disease. It can also 
help identify and counsel couples with the sickle cell trait who are at risk of having 
other children with sickle cell disease. However, providing information to parents 
5 McCabe, L.L.  and McCabe, E.R.B., ‘Genetic Screening: Carriers and Affected 
Individuals’, (00) 5 Annual Rev�ew� Genom��� Human Gene����, 57-69.
6 Working Party of the Clinical Genetics Society (A. Clarke, Chairman), ‘The Genetic            
Testing of Children’, (199) 31 J. Med Gene�., 785-97.
7 American Society of Human Genetics, American College of Medical Genetics 
(ASHG/ACMG), ‘Points to consider: Ethical, Legal and Psychological Implications of 
Genetic Testing in Children and Adolescents’, (1995) 57 Am. J. Hum. Gen., 133-1.
8 Wertz, D.C., Fanos, J.H.  and Reilly, P.R., ‘Genetic Testing for Children and 
Adolescents. Who Decides?’, (199) 7 J.A.M.A., 875-81.
9 Working Party of the Clinical Genetics Society,       �upra ���., note 6.
50 Working Party of the Clinical Genetics Society,       �upra ���.,  note 6; American society 
of Human Genetics, American College of Medical Genetics, �upra ���., note 7.
51 From the American Sickle Cell Association website: http://www.ascaa.org/comm.
htm.
5 Farriaux, J.P.  and Dhondt, J.-L. (eds), New Hor�zon� �n Neona�al S�reen�ng, Excerpta 
Medica, Amsterdam, 199; Knoppers, B.M.  and Laberge, C.M. (eds), Gene��� S�reen�ng: 
From Newborn� �o DNA Typ�ng, Excerpta Medica, Amsterdam, 1990.
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for decision-making is secondary to the primary reason for neonatal screening.53 In 
short, where screening can detect a treatable disease and at the same time reveal 
carrier status, the recommendations are that parents be advised of this possibility 
before the test and that results be given to the parents, in combination with any 
necessary counselling.5
Informing, educating and counselling families of carriers identified by newborn 
screening are major challenges from a logistical perspective; adequate funding is 
needed for comprehensive educational programme care. As mentioned earlier, a 
universal newborn screening programme would potentially identify thousands of 
carriers who require primary health care workers to provide counselling.55 There 
are few studies that report on the way health services are organised for children 
with SCD or for carriers of the SC trait.56 In fact, very little is known about who 
informs parents about SC screening, whether information is provided before or after 
screening, what expertise the health providers have, or what type of information is 
provided and in what form. We also do not know what happens to carriers of the SC 
trait: are parents are informed? Are they offered counselling? Are parents and other 
family members offered screening to determine if they are carriers? Who ensures 
that the child is told upon reaching adolescence?
The long-term use of carrier status information impacts on consent issues. Many 
official policies concerning carrier status strongly advise against notifying the child, 
particularly because of the relative absence of programmes to support counselling.57 
Not only does this mean that the child has been tested without his or her consent, but 
he or she is also effectively denied relevant reproductive information.
Certain questions must be answered before implementing universal screening 
programmes capable of detecting carriers. For instance, should screening be 
conducted without prior consent, seeing as it can yield genetic information which 
some parents would prefer not knowing? How and under what circumstances should 
information about the sickle cell trait be conveyed to parents? Is it ethically justifiable 
not to inform parents if their child is a carrier of the sickle cell trait? Is it ethically 
acceptable to screen newborns when adequate education and counselling cannot be 
provided? If SCD screening is implemented, how will it affect newborn screening 
for treatable conditions?
53 Council of Regional Networks for Genetic Services, �upra note .
5 British Medical Association, Human Gene���� C�o��e and Re�pon��b�l��y, London, 
Oxford University Press, 1998, at p. 100.
55 World Health Organisation (WHO), Con�rol of Hered��ary D��ea�e – Repor� of a 
WHO Scientific Group, Geneva, 1996.
56 See Goldbloom, R.B., ‘Screening for Hemoglobinopathies in Canada’, in Canadian 
Task Force on the Periodic Health Examination, Canad�an Gu�de �o Cl�n��al Preven��ve Heal�� 
Care, Ottawa, Health Canada, 199; Yorke, D., Mitchell, J.,  e� al., ‘Newborn screening for 
sickle cell and other hemoglobinopathies: a Canadian pilot study’, (199) 15() Cl�n. Inve��. 
Med., 376-83.
57 �ane, P.A., �Issues Regarding Identification of �emoglobinopathy Carriers by 
Neonatal Screening’, (1998) 15 Gene��� Dr�f� (Newsletter).
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If SCD screening is conducted, parents will need to be given information about 
various subjects: for example, the significance of results and their right to accept or 
decline SCD screening or notification should they prefer not knowing about carrier 
status. 
T�e Con��ra�n�� of U��ng ���n����y a� a Pr�mary Tool for Sele���ve S�reen�ng
Race and geographical origin constitute a significant factor in the incidence of 
SCD. The disease mostly affects people whose ancestors are from Africa, India, 
the Mediterranean, the Caribbean, South and Central America and Middle Eastern 
countries. �owever, in multicultural, melting-pot societies, it may become difficult 
to determine individuals’ ethnicity or origin simply by looking at their skin colour. 
While resource-based arguments suggest that a targeted approach (selecting certain 
infants on the basis of race and ethnicity) for SCD screening is most efficient, the 
consensus view, based on practical experience in the UK,58 and the US experience in 
the state of Georgia,59 is that universal screening of all newborns for SCD is preferable. 
Programmes that screen in only specific high-risk segments of a population tend to 
miss individuals who are inaccurately registered. �ecause the benefits of screening 
for SCD are so compelling, leaving the selection based on ethnic and racial groups to 
the discretion of individual physicians or health care facilities has been abandoned in 
the United States60 and in the United Kingdom.61  Indeed, since SCD occurs among a 
wide range of ethnic and racial groups, efforts at targeting specific high-risk groups 
for newborn screening inevitably miss some affected infants because of difficulties in 
properly assigning race or ethnic origin during the prenatal period or in the newborn 
nursery.6 Professional assessment of the mother’s race is often wrong.63 
Definition of the screened population is a controversial topic in haemoglobinopathy 
screening. Guidelines and reviews of screening programmes have been published by 
various agencies around the world. Some have recommended universal screening 
for all newborns, while others have suggested that screening strategies, whether 
universal or selective, should depend on the proportion of high-risk individuals in 
a community.6 One of the problems with targeted screening lies in the difficulty 
of identifying and selecting individuals. For instance, investigators in Georgia, 
US, compared the number of black newborns screened for haemoglobinopathies 
58 Sassi, F., Archard, �. and �e Grand, �., ��quity vs efficiency: A Dilemma for the 
NHS’, (001) 33 B.M.J., 76-3; Panepinto, J.A., Magid, D., Rewers, M..J. and Lane, P.A., 
‘Universal Versus Targeted Screening of Infants for Sickle Cell Disease: A Cost-Effectiveness 
Analysis’, (000) 136 J. Ped�a�r���, 01-8.
59 Harris, M.S.  and Eckman, J.R., ‘Georgia’s Experience with Newborn Screening: 
1981-1985’, (1989) 83(suppl.) Ped�a�r���, 858-60.
60 NIH Consensus Development Program, �upra ���., note 8.
61 NHS Sickle Cell and Thalassaemia Screening Programme, �upra ���., note 3.
6 Goldbloom, �upra ���., note 56.
63 Wertz, �upra ���.,  note 1.
6 Goldbloom, �upra ���., note 56.
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between 1981 and 1985 with black birth figures for the same period, and estimated 
that approximately 0 percent of black newborns were not screened.65 Results of a 
study of universal screening in multiethnic California also indicated that an approach 
of targeting certain groups in that state would have missed at least 10 percent of 
those whose sickle cell disease was actually diagnosed at birth.66 Indeed, the US 
experience suggests that adequate targeting strategies are difficult to define and the 
criteria used to identify ethnic origin in relation to risk of sickle carrier status are 
likely to vary between and within countries, thus making the generalisability of such 
analyses difficult to interpret.67 
Critics of the targeted approach have also raised the issue of the cost of 
determining race and ethnicity in the newborn nursery.68 Another criticism is that 
a selective approach could be seen as discriminatory.69 Before implementing a 
newborn screening programme for SCD, policy-makers will need to consider 
whether universal screening in a given area constitutes a rational policy.
Pol����al Pre��ure by Advo�a�y Group�
Newborn screening for PKU, developed in the 1960s, originated with the work of 
Robert Guthrie, a highly motivated parent who had a son with mental retardation 
and a niece with PKU.70 He helped organise parents to lobby their governments to 
establish newborn screening programmes. Similarly, parents today continue to press 
for screening programmes.71 
Partnership and public consultation have become important tools in policy 
development because they increase legitimacy and improve transparency in the 
policy development process. A review of the literature on public consultation and 
involvement shows that public involvement in policy development is no longer limited 
65 Harris, Eckman, �upra ���., note 59.
66 Shafer, F.E., Lorey, F., Cunningham, G.C., Klumpp, C., Vichinsky, E.  and Lubin, 
B., ‘Newborn Screening for Sickle Cell Disease:  Years of Experience from California’s 
Newborn Screening Program’,  (1996) 18(1) J. Ped�a�r. Hema�ol. On�ol., 36-1.
67 Lees, C.M., Davies, S. and Dezateux, C., ‘Neonatal Screening for Sickle Cell Disease 
(Cochrane Review)’, in T�e Co��rane L�brary, Issue 3, Chichester, UK, John Wiley & Sons, 
00. 
68 Lane, J.R. and Eckman, P.A., ‘Cost-effectiveness of Neonatal Screening for Sickle 
Cell Disease’, (199) 10(1) J. Ped�a�r���, 16-3; Cronin, Normand, Henthorn, Hickman, 
Davies, �upra ���., note 3.
69 Sassi, Archard, LeGrand, �upra ���., note 58.
70 McCabe and McCabe, �upra ���., note 5.
71 Guthrie, P., ‘Pressure Mounts to Expand Screening of US Newborns’, (005) 173(1) 
J.A.M.C., ; See March of Dimes: https://www.marchofdimes.com ; See also Genetics 
Interest Group: http://www.gig.org.uk ; Eggertson, L., ‘Canada Lags on Newborn Screening’, 
(005) 173 C.M.A.J., 3; Gillot, J., ‘Childhood Testing for Carrier Status: the Perspective of 
the Genetic Interest Group’, in Clarke, A. (ed.), T�e Gene��� Te���ng C��ldren, Oxford, Bios 
Scientific Publishers, 1998, at p. 97.
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to the reactions to particular services or products.7 As early as 1986, the Ottawa 
Charter73 emphasised the importance of public health and promotion and greater 
consultation with the public. The belief is that the result of involving communities 
of users, the public, and the health professionals will be greater harmonisation and 
successful implementation of an initiative or programme. The partnership of parents 
and health professionals will encourage the dissemination of balanced information.7 
These steps need encouragement, and many drawbacks to effective implementation 
exist: there are wide gaps in knowledge, language barriers, cultural differences, and 
economic issues, and there are also time constraints.75 
What is known about the views and experience of families and health 
professionals? For example, the public needs to understand the difference between 
carrier status and clinical diagnosis.76 There is insufficient information about family 
values and expectations with regard to SCD screening. It is important to consult high-
risk populations to understand if identified infants are being enrolled in a programme 
for treatment and care, if certain types of services or programs are deemed necessary 
to prevent the birth of children with the disease, and if there is a need for community 
education, couples counselling, and/or carrier screening to all high-risk populations 
of childbearing age.
Research on other screening programmes suggests that the perspectives of 
health professionals differ from those of parents. According to a survey by Wertz 
on topics relevant to the genetics of paediatrics, the views of parents and primary 
care physicians differ significantly. Increasingly, parents do not accept a paternalistic 
approach but rather believe that nothing should be withheld from them.77 
Furthermore, there is an inadequate number of certified counsellors to respond 
to the need for support.78 While medical care personnel are increasingly exposed to 
genetics, difficulties in the interpretation of DNA reports raise important educational 
challenges. There are also concerns about resources available to establish newborn 
follow-up and trait counselling programs. For example, in the USA,79 counselling to 
7 Butler, A., Con�umer Par����pa��on �n Au��ral�an Pr�mary Care: A L��era�ure Rev�ew, 
Australia, National Resource Centre for Consumer Participation in Health, 00.
73 1st International Conference on Health Promotion, O��awa C�ar�er, Ottawa, November 
1986.
7 National Health and Medical Research Council and Consumers’ Health Forum of 
Australia, S�a�emen� on Con�umer and Commun��y Par����pa��on �n Heal�� and Med��al 
Re�ear��, Australia, 001.
75 Hamlett, P.A., ‘Technology Theory and Deliberative Democracy’, (003) 8(1) 
S��en�e Te��nology and Human Value�, 11-10.
76 McCabe and McCabe, �upra ���., note 5.
77 Wertz, �upra ���.,  note 1.
78 Task Force on Life and the Law, ‘Genetic Testing and Screening in the Age of 
Genomic Medicine’, New York, November 000, http://www.health.state.ny.us/nysdoh/
taskfce/screening.htm. 
79 Day, S.W., Brunson, G.E. and Wang, W.C., ‘Successful newborn sickle cell trait 
counselling program using health department nurses’, (1997) 3 Ped�a�r�� Nur�e, 557-61.
Newborn S�reen�ng for S��kle Cell D��ea�e: So��o-�����al Impl��a��on� 505
families with infants with a trait is either very limited in scope or non-existent and 
with little follow-up facilities. Follow-up of SCD is often fragmented and acceptance 
of counselling is low.80 
Finally, in the care of carrier status, there is uncertainty about how best to inform 
parents about the diagnosis of the sickle cell trait in the newborn.81 The possible 
benefits for the child are educational and useful only when the child is older. 
�owever, it is unclear whether informing parents is beneficial to the child and how 
best to inform parents. Hence, focusing more on the needs, wants, and opinions of 
parents is key to facilitating participation and to helping with the presentation of 
information materials.
Conclusion
Neonatal screening for SCD allows early diagnosis and therefore early treatment 
and education. However, such a screening programme must take into consideration 
a number of socio-ethical concerns. 
We presented three main socio-ethical concerns with respect to SCD neonatal 
screening. First, the need to address the difficulties raised by revealing carrier status; 
second, whether neonatal screening should be selective or universal; and third, the 
need to address the role of consumer groups if screening is to reach its promise of 
predictive and preventive aspects.
Neonatal screening can detect most high-risk infants, but what should be 
communicated about carrier status? Ultimately, the identification of carriers calls for 
a re-examination of classical newborn screening consent procedures. How to do this 
without affecting or harming the newborn screening programme for immediately 
treatable conditions is the central issue. Deciding to screen for SCD and identifying 
carriers raise wider questions regarding parents’ rights to refuse newborn screening 
for sickle cell diseases. Consequently, newborn screening for SCD cannot be carried 
out in the same manner as screening for treatable conditions occurs today because 
of the ethical issues related to carrier identification in the former. Informed consent 
with a clear understanding of the potential social and psychological harms is a key 
ethical issue. Considering the possible ‘harm’ of SCD consent process on classical 
screening programs, should SCD be universal or selective?
There is a difference of opinion about whether SCD screening should be selective 
or universal, and there is even less consensus on whether or how ethnicity or race 
should be used in selective screening programmes for sickle cell disorders. Experts 
debate whether it should be decided on the basis of proportion of the population 
from ethnic minorities, whether it is cost-effective without the risk of reduced 
80 Kladny, B., Gettig, E.A. and Krishnamurti, L., ‘Systematic follow-up and case 
management of the abnormal newborn screen can improve acceptance of genetic counselling 
for sickle cell or other hemoglobinopathy traits’, (005) 7 Gene���� �n Med���ne, 139-.
81 P.T. Rowley, �Parental Receptivity to Neonatal Sickle Trait Identification/, (1989) 
Ped�a�r���, 891-3.
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effectiveness, and whether there is risk of discrimination. The best way to address 
this dilemma is to improve available data on cases of SCD, carrier rates, and by using 
standardised instruments for collecting ethnicity data.8 Neonatal programs have the 
ability to identify newborns with SCD and identify carriers of the SC trait. Estimates 
indicate that about half of all infants in the UK who are carriers have mothers who 
are carriers.83 Some say that it is more economical to ask women about their ethnic 
origin and offer screening only to those with genetic backgrounds in areas where 
the disorder is highly prevalent. Others suggest that such policies miss a significant 
number of affected cases because the screening criteria might be inadequate and 
inconsistently applied.
Finally, how can we best involve the parents? Obviously, there is a need for 
appropriate information and counselling prior to screening and for appropriate 
resources as well for adequate follow-up services. This should be combined with 
educational programmes and resources. Public interest in sickle cell disease has 
prevailed since Robert Guthrie’s initiative in the 1960s. The involvement of ethno 
cultural groups and their representatives in assessing the risks and benefits of neonatal 
screening for sickle cell is needed. Generally, recommendations regarding such a 
programme are derived from professionals or bioethicists and the voice of parents 
– consumers – is rarely heard at the discussion table.8 The drive towards more equal 
partnerships in decision-making in health programmes implies the need to promote 
and initiate dialogue with parents on a range of these socio-ethical issues.
Despite the socio-ethical quandaries of carrier identification, targeted versus 
universal approaches, and, in part, because of the experience of pressure from 
parents, newborn screening programmes for sickle cell disease have been introduced 
in numerous countries. Based on lessons from the past, it is important that genetic 
counsellors in sickle cell screening programmes discuss the confidentiality of 
results and the potential for genetic discrimination by life and medical insurance 
companies with families, to ensure that they understand the significance of carrier 
identification. It is also vital that policy-makers provide proper public education so 
that discriminatory practices do not take place. 
Perhaps a novel way to change the contours of the debate would be to take 
the best interests of the child approach. Where, when, and how can those interests 
be ensured? Though many answers to our research questions are still lacking and 
the social constraints of resources or failures such as discrimination are important 
political and systemic issues, to answer the SCD questions, the rights and interests 
of the child should be paramount.
8 Hickman, M., Modell, B., Greengross, P., Chapman, C., Layton, M., Falconer, S. and 
Davies, S.C., ‘Mapping the Prevalence of Sickle Cell and Beta Thalassaemia in England: 
�stimating and Validating �thnic-specific Rates’, (1999) 104 Br. J. Haema�ol., 860-7.
83 NHS Sickle Cell and Thalassaemia Screening Programme, �upra ���., note 3.
8 Wertz, D.C. and Gregg, R., ‘Genetics services in a social, ethical and policy context: 
a collaboration between consumers and providers’, (000) 6 Journal of Med��al ������, 
61-5.
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